Lithium citrate

• Description:

  Lithium citrate is a lithium supplement that reduces excess brain N-acetylaspartate (NAA) in Canavan disease. Canavan disease is an autosomal recessive leukodystrophy caused by mutations in the aspartate acylase (ASPA) gene, which catalyzes the hydrolysis of N-acetylaspartate (NAA) to acetate and aspartate[1].

• Product Name Alternative:

  Litarex

• UNSPSC:

  12352211

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Others

• Type:

  Reference compound

• Related Pathways:

  Others

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/lithium-citrate.html

• Purity:

  98.0

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(CC(C(O[Li])=O)(CC(O[Li])=O)O)O[Li]

• Molecular Formula:

  C6H5Li3O7

• Molecular Weight:

  209.92

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Mitra Assadi, et al. Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease. Eur J Paediatr Neurol. 2010 Jul;14 (4) :354-9.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, stored under nitrogen)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [919-16-4]